We are temporarily experiencing longer than normal turnaround times and your test may take up to 2 weeks longer than usual to report. Please contact support.us@blueprintgenetics.com with questions.
Blueprint Genetics is a genetic testing company focused on inherited diseases. With a patient-first mindset, we deliver high-quality genetic testing to the global clinical community across 15 medical specialties. Blueprint Genetics is based in Helsinki and Seattle, with a customer base spanning over 70 countries.
What we do
We provide high-quality genetic testing for a global clinical community. By combining a state-of-the-art laboratory process, the latest sequencing technology, AI empowered data-crunching tools and techniques, world-class professionals, and a holistic customer experience approach, we are bringing genetic knowledge to mainstream healthcare.
Our promise
We provide clinicians and their patients with comprehensive and high-quality tools and resources for diagnosis of genetic conditions. In doing so, we provide possibilities for targeted treatment and individualized care for patients.
Are you the one?
Become part of something that makes a difference. Join our team and help us develop industry-changing solutions for the benefit of patients and families living with inherited diseases.
Tommi leads Blueprint Genetics as VP & GM of Specialty Genetics and is also a co-founder of the company. He has been running Blueprint Genetics since the beginning, growing the company into a leading clinical genetic testing provider. Over time he has held various responsibilities focused around sales and marketing, organizational development, business development and financing. Prior to Blueprint Genetics he founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a MSc (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Juha is the Executive Director of Medical & Lab Director at Blueprint Genetics. He is a co-founder of the company as well. Juha is responsible for supervising laboratory production and for designing new diagnostic tests. On a daily basis, he participates in the clinical evaluation of genetic findings and further develops the company's variant classification and interpretation practices in collaboration with a team of geneticists. Juha has an MD-PhD from the University of Turku. In 2006, Juha completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the University of California San Francisco’s Cardiac Stem Cell Translational Development Program as a postdoctoral researcher and later as a research specialist. He also teaches at the University of Helsinki.
Samuel is the Executive Director of Strategy at Blueprint Genetics as well as a co-founder of the company. He is an expert in genome analysis technologies and has extensive experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and completed his postdoctoral research at Stanford University. At Stanford, he developed high-throughput sequencing technologies such as Oligonucleotide-Selective Sequencing (OS-Seq™). He is an adjunct professor in genetics at the University of Helsinki, an author of several high-impact publications, and an inventor and patent holder of DNA sequencing methods.
Tero-Pekka is the Executive Director of Medical, and also a co-founder at Blueprint Genetics. He is based in San Francisco and holds various responsibilities in the North American operations of the company. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular disease.
Spark Therapeutics joins as a new collaborator to the My Retina Tracker® Genetic Testing Program to broaden access for individuals living with an inherited retinal degeneration (IRD).
